Still, less than 25% of patients benefit from these drugs, which are designed to block proteins that stop the immune system from attacking cancer cells. And in many cases, that benefit is temporary. Compounding all of that is the difficulty in telling, in a timely fashion, if the treatment is working at all. That kind of critical feedback can determine whether a patient should stay the course or move onto an alternative therapy. Read more . . .
Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies. It’s because they work better than the previous standard of care.